Haleon PLC Announces Director Shareholding Transaction

The latest update is out from Haleon PLC ( (GB:HLN) ).

Haleon PLC announced a transaction involving a Person Discharging Managerial Responsibilities, Marie-Anne Aymerich, who acquired ordinary shares through dividend reinvestment. This transaction, conducted on the London Stock Exchange, reflects the company’s adherence to UK Market Abuse Regulation requirements and highlights its ongoing commitment to transparency and regulatory compliance.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s overall stock score is driven by its strong financial performance and positive earnings outlook. However, overvaluation concerns and mixed technical indicators temper the score. The company’s proactive capital management through share buybacks further supports its market standing.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers a diverse product portfolio across six major categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted and innovative brands, including Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.

Average Trading Volume: 27,396,065

Technical Sentiment Signal: Buy

Current Market Cap: £35.16B

See more data about HLN stock on TipRanks’ Stock Analysis page.